CNS Pharmaceuticals Faces Nasdaq Delisting Warning

TL;DR

Nasdaq says CNS Pharmaceuticals stock price too low, needs to hit $1 for 10 days by Jan 16 or get booted.

AI Summary

CNS Pharmaceuticals, Inc. received a notice on July 19, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has 180 calendar days, until January 16, 2025, to regain compliance by achieving a minimum closing bid price of $1.00 per share for at least 10 consecutive business days.

Why It Matters

Failure to regain compliance could result in the delisting of CNS Pharmaceuticals' stock from the Nasdaq, significantly impacting its liquidity and investor confidence.

Risk Assessment

Risk Level: high — The company is at high risk of delisting from the Nasdaq if it cannot meet the minimum bid price requirement within the specified timeframe.

Key Numbers

• $1.00 — Minimum Bid Price (Required to regain Nasdaq listing compliance)
• 10 — Consecutive Business Days (Duration for minimum bid price to be met)
• 180 — Calendar Days (Timeframe to regain compliance)

Key Players & Entities

• CNS Pharmaceuticals, Inc. (company) — Registrant
• Nasdaq Capital Market (company) — Listing exchange
• July 19, 2024 (date) — Date of notice
• January 16, 2025 (date) — Compliance deadline
• $1.00 (dollar_amount) — Minimum bid price requirement

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share CNSP The NASDAQ Stock Marke
• $2,500,000 — was not in compliance with the minimum $2,500,000 stockholders' equity requirement for co

Filing Documents

• cns_8k.htm (8-K) — 27KB
• 0001683168-24-005023.txt ( ) — 198KB
• cnsp-20240719.xsd (EX-101.SCH) — 3KB
• cnsp-20240719_lab.xml (EX-101.LAB) — 33KB
• cnsp-20240719_pre.xml (EX-101.PRE) — 22KB
• cns_8k_htm.xml (XML) — 4KB

01. Notice of Delisting or Failure to Satisfy a Continued

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 17, 2023, CNS Pharmaceuticals, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that it was not in compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing set forth in Listing Rule 5550(b). On February 14, 2024, the Company was notified that because it had not regained compliance with the Nasdaq stockholders' equity requirement, the Company's securities would be delisted unless it timely requested a hearing. On February 21, 2024, the Company requested a hearing, which had the effect of staying any suspension or delisting action pending the conclusion of the hearings process. On May 6, 2024, the Company received notification from the Nasdaq Hearings Panel ("Panel") that it had granted an extension until July 15, 2024, to demonstrate compliance with Listing Rule 5550(b). On July 12, 2024, the Company requested an extension of this time period until August 12, 2024. On July 19, 2024, the Panel granted the requested extension until August 12, 2024, which date represents the full extent of the Panel's discretion to grant continued listing while the Company is non-compliant with Listing Rule 5550(b). 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CNS Pharmaceuticals, Inc. By: /s/ Chris Downs Chris Downs Chief Financial Officer Dated: July 24, 2024 3